NIH Cuts Would Mean Dozens of New Drugs Could Be Lost, CBO Says. That’s Probably an Undercount
Shares:
Programming Note: Unless someone misbehaves, Cost Curve will be off tomorrow. Back Monday. If you need extra Cost Curve content over the weekend, I sat down with Incubate’s John Stanford
Well, this is a fitting end to a wild week. We now have the 15 medicines that will go through the next round of price-setting “negotiations” with CMS. Here are
Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv